BACKGROUND INFORMATION ON THE PROCEDURE 
1. 
Submission of the dossier 
The  applicant  Orphan  Europe  submitted  on  22  October  1997  an  application  for  Marketing 
Authorisation to the European Agency for the Evaluation of Medicinal Products (EMEA) for Phenbut, 
through the centralised procedure. During the procedure, the name was changed to Ammonaps. After 
agreement by the CPMP on 17-19 February 1997, this medicinal product is referred to Part B of the 
Annex to Council Regulation No. (EC) 2309/93 of 22 July 1993. 
The Rapporteur and Co-Rapporteur appointed by the CHMP were: 
Rapporteur:  Dr. D.Lyons  
Co-Rapporteur:  Dr. J.Yotaki 
Licensing status: 
US orphan status designation was on 22 November 1993. The product was approved in the USA on 30 
April 1996. 
2. 
Steps taken for the assessment of the product 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
The procedure started on 30 January 1998. 
During the on 24-25 February 1998, the CPMP rejected the proposed tradename Phenbut. 
During  its  meeting  on  23-25  March  1998,  the  CPMP  agreed  on  an  inspection  of  the 
manufacturing facility for the bulk finished product (i.e. Pharmaceutics International Inc., Hunt 
Valley, USA). 
The Rapporteur's first assessment report was circulated to all CPMP Members on 9 April 1998 
(Annex 1). The Co-Rapporteur's first assessment report was circulated to all CPMP Members on 
14 April 1998 (Annex 2) 
The summary report of the inspection carried out at the finished product manufacturing site (i.e. 
Pharmaceutics International Inc., Hunt Valley, USA) between 13-15 May 1998 concluded that 
the operations are in general compliance with the principles and guidelines of GMP (Annex 3). 
During the meeting on 25-27 May 1998 the CPMP agreed on the consolidated list of questions 
to be sent to the company. The final consolidated list of questions was sent to the company on 
29 May 1998  (Annex 4). 
On 3 August 1998, the applicant proposed a new tradename Ammonaps, which was accepted by 
the CPMP during its meeting on 20-22 October 1998.  
The  company  submitted  the  responses  to  the  CPMP  consolidated  list  of  questions  on  
4 December 1998. 
On  15  January  1999,  the  Rapporteur  circulated  to  all  CPMP  Members  a  scientific  overview 
report on the company’s responses to the list of questions, highlighting outstanding Part II and 
bioequivalence  issues.  During  its  meeting  on  26-27  January  1999,  the  CPMP  agreed  on  the 
second list of outstanding questions to be addressed by the applicant (Annex 5).  
The  company  submitted  the  responses  to  the  second  list  of  outstanding  questions  on  
27 April 1999. 
The  Rapporteur  and  the  Co-Rapporteur  circulated  their  joint  assessment  report  on  the 
company’s responses to all CPMP Members on 30 June 1999 (Annex 6). 
The CPMP, during its meeting on 27- 29 July 1999, discussed the recommendations presented 
by the Rapporteurs and the amendments to the Summary of Product Characteristics and Package 
Leaflet texts. 
1/2 
EMEA 2005 
 
 
 
 
 
 
 
 
 
• 
• 
• 
The  Marketing  Authorisation  Holder,  Orphan  Europe,  provided  a  letter  of  undertaking  on  the 
specific  obligations  as  requested  by  the  CPMP  (on  Chemical/pharmaceutical  and  clinical 
aspects), dated 29 July 1999 (Annex 7). 
During the meeting on 27-29 July 1999 the CPMP, in the light of the overall data submitted and 
the  scientific  discussion  within  the  Committee,  issued  a  positive  opinion  for  granting  a 
Marketing Authorisation under exceptional circumstances to Ammonaps on 29 July 1999. 
The  CPMP  opinions  were  forwarded,  in  all  official  languages  of  the  European  Union,  to  the 
European Commission, which adopted the corresponding Decisions on 8 December 1999. 
2/2 
EMEA 2005 
 
 
 
 
 
